CAS: 28274-57-9; Methaneseleninic Acid(6Ci,8Ci,9Ci)

上下游产品

dimethylselenide dimethyl diselenide nitric aciddimethylselenide dimethyl diselenide formaldehyd selenium(IV) oxide

二甲基二硒醚置于硝酸体系中,化学反应生成甲亚硒酸
参考文献:Backer; Van Dam,Recueil Des Travaux Chimiques Des Pays-Bas,1935,Vol. 54,P. 531
标题:Backer; Van Dam,Recueil Des Travaux Chimiques Des Pays-Bas,1935,Vol. 54,P. 531

专利信息

专利号:US-2007088086-A1
优先权日:1999-08-16
标题 :Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use for L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine, and phosphite to form a first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone. Methyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactone to form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine. The tert-butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteine to form L-Se-methylselenocysteine. This synthesis significantly improves the manufacturability, manufacturing efficiency, and utility of this naturally occurring rare form of organic-selenium. L-Se-methylselenocysteine formed, for example, in this manner may be used as a nutriceutical for supplementation into the diets of humans or animals for various beneficial purposes, such as, for example, to prevent or reduce the risk of developing cancer.

专利号:EP-1205471-A1
优先权日:2000-10-02
标题:A method of using synthetic L-SE-Methylselenocysteine as a nutriceutical and a method of its synthesis
发明人：SPALLHOLZ JULIAN E; REID TED W; WALKUP ROBERT D
权利人:PHARMASE INC
摘要:A synthesis of and use of L-Se-methylselenocysteine as a nutriceutical isndescribed, based upon the knowledge that L-Se-methylselenocysteine is lessntoxic than L-selenomethionine towards normal cells. The synthesis proceedsnby mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylatenand at least one of a trialkylphosphine, triarylphosphine and phosphite to formna first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone.nMethyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactonento form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine.nThe text butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteinento form L-Se-methylselenocysteine.nThis synthesis significantly improves thenmanufacturability, manufacturing efficiency and utility of this naturallynoccurring rare form of organic-selenium. L-Se-methylselenocysteine formed,nfor example, in this manner may be used as a nutriceutical for supplementationninto the diets of humans or animals for various beneficial purposes, such as, fornexample, to prevent or reduce the risk of developing cancer.

专利号:US-12187735-B2
优先权日:2018-09-17
标 题:Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease
发明人：LING XIANG; LI QINGYONG; LI FENGZHI
权利人:CANGET BIOTEKPHARMA LLC
摘要:Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.

专利号:US-2025092058-A1
优先权日:2018-09-17
标 题 :Matter of composition, synthesis, formulation and application of fl 118 platform positions 7 and 9-derived analogues for treatment of human disease
发明人：LING XIANG; LI QINGYONG; LI FENGZHI
权利人:CANGET BIOTEKPHARMA LLC
摘要:Described herein, are the chemical synthesis, compounds, methods and uses of the fluoroaryl-substituted derivatives at the FL118 position 7, which target multiple cellular human disease-relevant proteins and their signaling pathways.

专利号:US-6869652-B2
优先权日:2000-03-15
标 题 :Porous polymer/carrier solid phase reactants, method for producing same and the use thereof
发明人：KUNZ ULRICH; KIRSCHNING ANDREAS; HOFFMANN ULRICH
摘要:Disclosed are porous polymer/carrier solid phase reactants which consist of a polymer that consists of fine particles and is situated in the pore space of porous carrier materials. Reactive groups are bound to the polymer. Said groups act as reactants in organic-chemical syntheses. Said solid phase reactants can be produced as bulk material or tubes, plates or rods, can be built in pressure sealed housings and can be used in flow-through apparatuses or microtitration fields for the synthesis of organic products. Potential active agents can be produced at high speed by using the inventive porous polymer/carrier solid phase reactants that can be flown through convectively, whereby production requires only little isolation and cleaning.

专利号:CA-3111403-A1
优先权日:2018-09-17
标 题:Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease